Skip to content

Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid

Psoriasis: assessment and management of psoriasis. T., Pettersson, U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238244. We assessed the variation in scoring psoriasis severity within (intrarater) and among (interrater) physicians. Fredriksson T, Pettersson U: Severe psoriasis: Oral therapy with a new retinoid.

Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid 2Phototherapy is highly effective in the therapy of psoriasis, but patient access to phototherapeutic facilities is not universal. Fredriksson and Pettersson, 1978; T. Fredriksson, U. Pettersson. Severe psoriasis-oral therapy with a new retinoid. Amevive (alefacept): For moderate to severe chronic plaque psoriasis. New approved drug details including side effects, uses and general information. Engl J Med 2001; 345:248-255. Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157:238-244. Methods for rating the severity of psoriasis in a patient are provided. PASI was developed in 1978 by Fredricksson and Pettersson5 for use in a single clinical trial. Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid.

Methods: Pooled data from a phase 2 dose-ranging trial in psoriasis using brodalumab (antibody to interleukin-17 receptor A) were used to compare subjects with static physician global assessment (sPGA) 1 versus sPGA 0 and subjects with Psoriasis Area and Severity Index (PASI) 75 to. Pettersson U. Severe psoriasis oral therapy with a new retinoid. 2003;14:158-165. 17. Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.

Commercial Tanning Bed Treatment Is An Effective Psoriasis Treatment: Results From An Uncontrolled Clinical Trial

Tim Gunn, host of Project Runway, launches Fashion Therapy for Psoriasis 3

Total Skin Clearance Results In Improvements In Health-related Quality Of Life And Reduced Symptom Severity Among Patients With Moderate To Severe Psoriasis